3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
3
Completed
3
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Glioblastoma
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Lymphoma, Follicular
2
Glioma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Squamous Cell
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, B-Cell
1
Gliosarcoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
Carboplatin
103
Pemetrexed
96
pembrolizumab
78
Docetaxel
78
Cisplatin
72
Paclitaxel
70
Erlotinib Hydrochloride
50
Gemcitabine
48
Radiotherapy
42
Nivolumab
35
Bevacizumab
35
atezolizumab
24
Radiosurgery
24
durvalumab
20
Cyclophosphamide
17
130-nm albumin-bound paclitaxel
15
Vinorelbine
14
Taxes
14
Radiation
14
Etoposide
13
Ipilimumab
12
Albumin-Bound Paclitaxel
12
avelumab
11
Drug Therapy
10
Cetuximab
10
spartalizumab
9
Sorafenib
9
trametinib
8
osimertinib
8
capmatinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Non-Small-Cell Lung
×
poly ICLC
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled